Email to Josh at Endpoint News:
josh@endpointsnews.com
Josh,
I just read an article you wrote on Northwest Biotherapeutics May 13, 2021. I wanted to recommend another related story which is two-fold, first the successful trial and secondly the stock price manipulation as follows:
At New York Academy of Sciences on May 10, 2022 there was a scientific presentation of DC-Vax L which is a novel immunotherapy for GBM which basically takes the patient’s own cancer cells to train the immune system to attack it. They had amazing results above the current standard of care for overall survival and should line up for regulatory approval by the FDA. The stock price crashed before the statistics were presented, and continued even with exceptional news about a cure for cancers. A story about the trial success, stock price manipulation and the mechanisms still in place to promote this nefarious activity. How this illegal behavior destroys the biotech industry from getting new treatments to the patients who need the treatment. This company is also working on a cancer platform to treat a broad variety of cancers in the future. If they are financially choked before commercialization then the people who manipulate the stock for their own greedy motivations kill an effective treatment for cancer from getting to the patients. I am a small investor in Northwest Biotherapeutics so my opinion is biased. I would encourage investigating this story and other stories of killing companies illegally through Wall Street’s shorting practices.
Thanks for your time,
Margaret Monson
